Kheir A, Johannsdottir B, Grönn-Weiss A, Liu LL, Ullén A, Laurell A, et al. Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab. AO [Internet]. 2025 Oct. 3 [cited 2026 May 30];64:1355-64. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/44533